معرفی
Dr. Valerie Shilling is a Principal Research Fellow at Brighton and Sussex Medical School's Sussex Health Outcomes Research & Education in Cancer (SHORE-C) group. She rejoined SHORE-C in April 2023 after serving as Programme Manager for the national Cancer Quality of Life Survey at the NHS Cancer Programme. Her academic positions have included Research Fellow roles at Brighton and Sussex Medical School, University of Exeter Medical School, and University of Liverpool.
Dr. Shilling earned her BA (Hons) and PhD in Psychology from the University of Manchester. Her doctoral research focused on cognitive changes with normal aging. She is a Chartered Psychologist and Associate Fellow of the British Psychological Society.
Her research centers on psychosocial oncology, with particular expertise in health-related quality of life measurement, development of patient-reported outcome measures, and caregiver support. Dr. Shilling's work examines the impact of cancer treatments on cognitive function, develops tools to help patients manage treatment side effects, and creates communication training materials for healthcare professionals based on patient perspectives. Her recent publications show a strong focus on metastatic breast cancer, patient understanding of personalized medicine, and quality of life measurement in various cancer types.
- Principal Research Fellow, Brighton and Sussex Medical School (2023-present)
- Programme Manager, NHS England Cancer Programme (2021-2023)
- Research Fellow, Brighton and Sussex Medical School (2014-2020)
Dr. Shilling has secured research funding from organizations including ELI LILLY (for the IMPACTOR study on abemaciclib treatment) and Bristol-Myers Squibb (for the PROACT study on patient-reported outcomes). Her collaborative approach involves working closely with patients, caregivers, and healthcare professionals to ensure research addresses real clinical needs and translates effectively into practice.
Her laboratory, SHORE-C, conducts pragmatic research aimed at directly improving cancer care through better measurement of patient outcomes, development of supportive interventions, and enhancement of patient-provider communication. The group's work bridges academic research and clinical practice to optimize the cancer patient experience.
